Boothbay Fund Management, LLC Allogene Therapeutics, Inc. Transaction History
Boothbay Fund Management, LLC
- $3.37 Billion
- Q2 2024
A detailed history of Boothbay Fund Management, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 11,100 shares of ALLO stock, worth $31,968. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,100Holding current value
$31,968% of portfolio
0.01%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ALLO
# of Institutions
176Shares Held
132MCall Options Held
94.3KPut Options Held
112K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$53.9 Million1.08% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$47.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$23.6 Million0.0% of portfolio
-
State Street Corp Boston, MA7.67MShares$22.1 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$19.9 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $414M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...